P
Philip J. Rosenfeld
Researcher at University of Miami
Publications - 358
Citations - 32577
Philip J. Rosenfeld is an academic researcher from University of Miami. The author has contributed to research in topics: Macular degeneration & Optical coherence tomography. The author has an hindex of 77, co-authored 325 publications receiving 28506 citations. Previous affiliations of Philip J. Rosenfeld include Massachusetts Eye and Ear Infirmary & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
Emily Y. Chew,Traci E Clemons,John Paul SanGiovanni,Ronald P. Danis,Frederick L. Ferris,Michael J. Elman,Andrew N. Antoszyk,Alan J. Ruby,David H. Orth,Susan B. Bressler,Gary E. Fish,Baker Hubbard,Michael L. Klein,Suresh R. Chandra,Barbara A Blodi,Amitha Domalpally,Thomas R. Friberg,Wai T. Wong,Philip J. Rosenfeld,Elvira Agrón,Cynthia A. Toth,Paul S. Bernstein,Robert Sperdut +22 more
TL;DR: Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not reduce risk of progression to advanced AMD, but because of potential increased incidence of lung cancer in former smokers, luteIn + zexanthin could be an appropriate carotenoid substitute in the ARedS formulation.
Journal ArticleDOI
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
Steven D. Schwartz,Carl D. Regillo,Byron L. Lam,Dean Eliott,Philip J. Rosenfeld,Ninel Z. Gregori,Jean-Pierre Hubschman,Janet L. Davis,Gad Heilwell,Marc J. Spirn,Joseph I. Maguire,Jane Bateman,Rosaleen Ostrick,Debra Morris,Matthew Vincent,Eddy Anglade,Lucian V. Del Priore,Robert Lanza +17 more
TL;DR: The results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement.
Journal ArticleDOI
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
TL;DR: An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.
Journal ArticleDOI
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Anne E. Fung,Geeta A. Lalwani,Philip J. Rosenfeld,Sander R. Dubovy,Stephan Michels,William J. Feuer,Carmen A. Puliafito,Janet L. Davis,Harry W. Flynn,Maria Esquiabro +9 more
TL;DR: In this paper, an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with age-related macular degeneration (AMD) was evaluated.